The low worldwide prices for antibiotics, combined with the need to carefully ration sale of any powerful new drugs that come to market to preserve their efficacy, continue to dampen industry investment in desperately-needed treatments for new drug-resistant superbugs, according to a sweeping new report by the AMR Industry Alliance, released today. While civil society […] Continue reading ->
More public disclosure and information-sharing about drug prices and their R&D costs, is key to determining a fair price for essential medicines, concludes a series of five articles on fair pricing published Monday in the BMJ. The series, supported in part by the World Health Organization, highlights the increased priority drug price transparency is receiving […] Continue reading ->
The World Health Organization issued new guidelines for the treatment of multi drug-resistant (MDR) tuberculosis on Wednesday, prioritizing for the first time an all-oral treatment regimen. The new treatment recommends replacing the painful injectable drugs that patients had to endure under previous treatment guidelines with a shorter course of oral bedaquiline – one of only […] Continue reading ->
A new plan to dramatically accelerate global efforts to end tuberculosis, one of the world’s deadliest and oldest known infectious diseases, was launched Tuesday by the Stop TB Partnership in Jakarta. The fully-costed plan is based on commitments made at a 2018 United Nations High-Level Meeting on Ending TB (UNHLM) to reduce TB deaths by […] Continue reading ->
Criminal activity surrounding the manufacture, distribution and sale of falsified medicines is “on the rise” as a global health problem in many developing countries and in rich nations – especially online – but efforts to stem the growing health threat will require robust collective action by all stakeholders, a leading Novartis official warned Friday in […] Continue reading ->
The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading ->
For the second year running, some 37 organizations have launched a week-long mini campaign to raise awareness and promote action against falsified and substandard medicines.  This year’s annual Fight the Fakes week aims to mobilize the public and international global health community to speak up more assertively about the growing threat of fake or substandard […] Continue reading ->
[Drugs for Neglected Diseases Initiative] Geneva, Switzerland (29 November 2019) – The Indian pharmaceutical company Cipla has announced their commitment to price the ground-breaking new product Quadrimune, a “4‑in‑1” treatment for young children with HIV, at below a dollar a day. Quadrimune is currently under review by the US Food and Drug Administration (FDA) for use in children […] Continue reading ->
The lower house of the French parliament has approved a milestone requirement that pharmaceutical companies must disclose the amount of public funding that was used in the research and development of new medicines entering the national market, as well as allowing those contributions to be factored into negotiations over final drug pricing. After being initially […] Continue reading ->